OKYO MEXC RealStocks
Own real OKYO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:32:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
OKYO Pharma Limited (OKYO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.10, with a market capitalization of $57.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.08 to $3.20. This page covers its latest market performance, valuation, price trends and company information.
$57.99M | |
$1.10 | |
$1.13 | |
$1.08 | |
$1.11 | |
224.44K | |
132.87K | |
-- | |
$3.20 | |
$1.08 | |
-- | |
2026-03-31 |
OKYO Pharma Limited (OKYO) last closed at $1.10 as of 2026-11-19 00:31:00, down 0.45% ($0.00) from the previous close of $1.11.
During the latest regular trading session, OKYO traded between $1.08 and $1.13, with a volume of 224.44K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, OKYO Pharma Limited (OKYO) moved from $1.38 to $1.10, representing a decline of 20.00% ($0.28).
The stock traded between $1.08 and $1.45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 665.87 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.1%
OKYO is currently trading at $1.10, placing it 1.1% of the way from its 52-week low of $1.08 to its 52-week high of $3.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OKYO Pharma Limited (OKYO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to OKYO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between OKYO shares and USD.
OKYO Shares to USD
1.00 OKYO shares = 1.104 USD
Calculations are estimates based on the latest available price and are for reference only.